AMA: Use of BMI alone is an imperfect clinical measure
D.BaffesG
10.1038/s41418-019-0352-3 11 ChenH.LiZ.XuJ.ZhangN.ChenJ.WangG.et al (2023b)
The class now includes three types: GLP-1 agonists: Activate the GLP-1 receptor only (semaglutide, liraglutide, exenatide, dulaglutide, lixisenatide, orforglipron) Dual GLP-1/GIP agonists: Activate both GLP-1 and GIP receptors (tirzepatide) Triple agonists (investigational): Activate GLP-1, GIP, and glucagon receptors (retatrutide, in Phase 3 trials) GLP-1 Medications Compared: Full Comparison Chart Here's every GLP-1 medication currently FDA-approved, with the data you actually need to compare them side by side
et al, Growth hormone secretagogues: history, mechanism of action, and clinical development, JSCM Rapid Communications Vol
Molecular network-based drug prediction in thyroid cancer